On Thursday, the U.K.
Medicines and Healthcare products Regulatory Agency (MHRA) approved Novo Nordisk A/S' (NYSE:NVO) Wegovy pill, clearing the company's first daily oral weight-management treatment for adults with obesity or overweight conditions linked to weight-related health issues.
The approval gives eligible patients a non-injectable alternative to GLP-1-based weight-loss therapies.
MHRA Clears First Oral Wegovy Option According to Novo Nordisk, the newly approved Wegovy pill contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist.
The medicine is authorized for adults living with obesity, defined as a body mass index (BMI) of 30 kg/m² or higher, or for overweight adults with a BMI between 27 kg/m² and less than 30 kg/m² who have at least one weight-related condition.
